Medication use by XXXX survivors: a 1-year longitudinal study.

@entity1 @entity407 @entity101 @entity0 @entity6 @entity5 @entity102 @entity460
PURPOSE: The aim of this study is to characterize the patterns of medication use by @entity0 ( @entity0 ) survivors from diagnosis to 1  year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with @entity0 @entity1 diagnosed between December 2011 and June 2014. Data on the medication use of individual @entity1 were retrieved from prescription databases, supplemented by records from the National Electronic Health Records. The data covered the period from @entity0 diagnosis to 1  year post-chemotherapy. Medication types were classified according to the World Health Organization's Anatomical Therapeutic Chemical classification system, and medication for @entity102 was created by adapting a list of 20 @entity102 provided by the U.S. Department of @entity1 and Health Services. RESULTS: Of the 107 @entity1 involved in the study (mean age 51.1        8.4  years; 78.5  % Chinese), 46.7  % manifested non- @entity5 comorbidities, of which @entity101 (24.3  %) was the most prevalent, followed by @entity407 (13.1  %) and @entity6 (5.6  %). @entity460 channel blockers (12.1  %) and lipid-modifying agents (11.2  %) were the most common chronic medication types used before chemotherapy, and their use persisted during chemotherapy (10.3 and 11.2  %, respectively) and after chemotherapy (11.2 and 13.1  %, respectively). Hormonal therapy was the predominant post-chemotherapy medication (77.6  %). A statistically significant increase (p   <   0.0001) was observed in the mean number of chronic disease medication classes prescribed to @entity1 between the pre-chemotherapy (0.53        1.04) and chemotherapy (0.62        1.08) periods and between the chemotherapy and post-chemotherapy (1.63        1.35) periods. CONCLUSIONS: There is an increase in trend of chronic medication usage in @entity0 survivors after @entity5 treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results.
